Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Utility of Platelet Rich Plasma in Hair Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03376581
Recruitment Status : Completed
First Posted : December 18, 2017
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Margit Juhasz, MD, University of California, Irvine

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Platelet rich plasma (PRP) is an autologous preparation of human plasma with high concentration of platelets. Platelets release numerous growth factors, which stimulate cell proliferation and differentiation.

The purpose of this research is to investigate the potential of PRP injection for treatment of hair loss. Clinical outcomes will be assessed by noninvasive techniques including dermoscopy, multiphoton microscopy, optical coherence tomography, optical Doppler tomography and multispectral imaging.


Condition or disease Intervention/treatment Phase
Androgenetic Alopecia Procedure: Platelet rich plasma Early Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Utility of Platelet Rich Plasma in Hair Loss
Actual Study Start Date : November 28, 2017
Actual Primary Completion Date : February 20, 2019
Actual Study Completion Date : February 20, 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Prospective treatment Procedure: Platelet rich plasma
Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Hair density to measure the efficacy of treatment [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Hair count (number of hairs/0.65 cm2) [ Time Frame: 6 months ]
  2. Terminal hair density [ Time Frame: 6 months ]
  3. Anagen hair percentage [ Time Frame: 6 months ]
  4. Telogen hair percentage [ Time Frame: 6 months ]
  5. Anagen/telogen ratio [ Time Frame: After 3 and 6 months ]
  6. Changes in hair structure, diameter, and blood flow [ Time Frame: 6 months ]
    As measured by optical coherence tomography


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Over 18 years of age
  • Ability to understand and carry out instructions
  • Diagnosed with alopecia

Exclusion Criteria:

  • Inability to understand and.or carry out instructions
  • Pregnant women
  • Use of any topical medication (such as minoxidil or any other solution for hair growth), oral medication (finasteride, dutasteride, or antiandrogens), laser therapy, or chemotherapy, within the preceding 4 weeks.
  • Personal medical history of bleeding disorders
  • Personal medical history of platelet dysfunction syndrome
  • Anti-coagulation therapy or nonsteroidal anti-inflammatory drugs in the last 1 week.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376581


Locations
Layout table for location information
United States, California
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Hewitt Hall
Irvine, California, United States, 92697
Sponsors and Collaborators
University of California, Irvine
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Margit Juhasz, MD, Clinical Research Fellow, University of California, Irvine
ClinicalTrials.gov Identifier: NCT03376581    
Other Study ID Numbers: 2016-3239
First Posted: December 18, 2017    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia
Hypotrichosis
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical